Rogers Campbell

CMO Rogers Campbell sells 64,533 shares (44.3% of holdings) for $1.6M; stock -37.8% from 52-week high, company unprofitable

Rogers Campbell, Chief Medical Officer, sold 64,533 shares at $24.64 on 2026-04-01, reducing holdings from 145,535 to 81,002 shares (a -44.3% reduction). This sale occurs with the stock trading -37.8% from its 52-week high of $39.91, suggesting the transaction took place in a depressed price environment relative to recent history. The company itself reported negative net income of $-50,855,000.00 for its most recent full fiscal year despite 39.9% annual revenue growth, indicating operational challenges despite top-line expansion. Campbell's cross-ticker track record shows 2 prior open-market sells with an average 30-day return of -16.3%, while his prior HTFL trades include a sale on 2026-02-12 that returned -16.3% over 30 days; the timing pattern shows 0 of 0 prior sells were well-timed at the 90-day mark, though sample sizes remain limited.

CMO Rogers Campbell sold 64.5K shares of HTFL at $25.69, reducing stake by 45.1%, in financially troubled company.

Rogers Campbell, Chief Medical Officer of Heartflow Inc., executed a substantial sale of 64,533 shares at $25.69 on 2026-03-19, reducing his holdings from 143,051 shares to 78,518 shares. The company remains unprofitable with net income of $-50.9M against revenue of $46.3M in its latest quarter, despite annual revenue growth of +39.9%. The stock trades 32.8% below its 52-week high of $39.91, and Campbell's prior sell at this ticker produced a -16.3% 30-day return with no measurable 90-day outcome yet. This magnitude of stake reduction by a chief medical officer at a cash-burning biotech warrants investor attention to whether it reflects broader capital allocation concerns or reflects individual portfolio adjustments.

CMO Rogers Campbell sells 65,153 shares of HTFL at $24.49; stock -44.2% from 52-week high, company burning $50.9M quarterly.

Rogers Campbell, Chief Medical Officer, sold 65,153 shares (65.2K shares) at $24.49 on 2026-02-12, reducing his holdings by 46.1% from 141,187 shares to 76,034 shares. The sale occurred against a backdrop of severe price deterioration: the stock is -44.2% from its 52-week high of $39.91 and -40.1% over the past 30 days. More significantly, Heartflow is posting negative quarterly net income of $-50,855,000.00 ($-50.9M) against quarterly revenue of $46,276,000.00 ($46.3M), indicating substantial cash burn that constrains runway. A near-halving of the CMO's equity stake by an insider responsible for clinical and medical strategy—during a period of sharp stock decline and operational losses—signals reduced confidence in the company's near-term trajectory and may reflect concern about the sustainability of the current burn rate.